The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.
Werewolf Therapeutics, a US-based cancer treatment developer backed by healthcare provider UPMC and pharmaceutical firm Taiho, has raised $120m in an initial public offering on the Nasdaq Global Market.
The company had initially filed to issue 6.25 million shares and set a price range between $15 and $17, but later upped the number of shares in the offering to 7.5 million and priced them at $16.00 each. It floated last week and its shares closed at $16.26 yesterday,…
